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ABSTRACT
Aim: To document and describe the individual patient lIse (IPU)
scheme at St Vincent's Hospital. Sydney in tenns ofsubmissions
and approvals and assess the financial impact ofthe scheme on the
hospital drug expenditure.
Method: All submissions for IPU approvals received between
January 1997 and December 2001 were reviewed. Submissions
were collected on a calendar year basis. Data collection and
analysis included identification of approved medication and
indication, ofT-label or approved indication, prescriber, ward,
outcome of therapy, person deciding the approval, approval
date duration and expiry, amount of medication dispensed and
the cost of therapy. The annual cost and proportion of overall
drug expenditure for each approval was calculated.
Results: The number ofapprovals had a trend to increase each
year. 67.1 % ofthe IPU approvals were for off-label indications.
Requested feedback on clinical outcomes was provided only in
18% of cases. The drug acquisition cost of the IPU scheme
more than doubled in the period between 1999 and 2001.
Similarly the proportion of the drug expenditure on IPU drugs
increased significantly (p < 0.001) from 1.6% in 1999 to 3.6%
in 2001.
Conclusion: The results indicated that the number ofapprovals
and submissions for IPU had a tendency to increase. The financial
impact of the fPU scheme increased over the years reviewed.
J Pharm Pract Res 2004; 34: 100-3.
INTRODUCTION
There are different mechanisms to fund medications in the
Australian healthcare system. One of these mechanisms
is the Pharmaceutical Benefits Scheme (PBS), which
subsidises drugs dispensed in community phannacies and
private hospitals and is funded by the Commonwealth
Government.! A number of public hospitals in some States
have implemented the PBS as a funding mechanism for
outpatient and discharge medications.2
The Commonwealth Government also provides
funding to the States and Territories for Section 100 or
the Highly Specialised Drugs (HSD) Program. These
are expensive drugs used for chronic conditions such
as cancer, HIV and organ transplantation. They are
prescribed by specialists and dispensed through
selected hospital pharmacies. Hospitals are responsible
for the drug cost of inpatients on HSD. If drugs are
prescribed for approved conditions, reimbursement is
sought by the hospital, otherwise the hospital will incur
the whole cost.!
The Commonwealth Government gives funding to
the States and Territories for public hospitals and other
Gluelle Gnllcgo, BPharm Chem. PhD candidate, Faculty of Pharmacy. The
University of Sydney. Camperdown, Terry Meloeco, BPharm, Director of
Phannacy, St Vincenl's Hospital. DarJinghurst. Suslln J TIl)·lor. BPhann, MSc
(Clinical), PhD. Senior Lecturer. Jo-anne E Brien, BPhann. BS (Pharm), PhannD,
Pharmllcia Chair in Clinical Pharmacy (St Vincent's Hospital), Faculty of
Phannllcy. The University of Sydney. Campcrdown. New South Wales
Address for correspondence: Profcssor Jo-anne Brien. Faculty of Pharmacy.
Thc University of Sydney, Building A15. Campcrdown NSW 2006. Austntlia
E-mail: jebrien@pharrn.usyd.edu.au
state-based programs. J In contrast to the uncapped
budget for the PBS and HSD program, public hospitals
deal with capped budgets and scarce resources. 3,4 In order
to deal with these restrictions, public hospitals need to
have cost containment strategies in place.s.nThe Drug
and Therapeutics Committee (DTe) at SI Vincent's
Hospital, Sydney has the task of constraining drug costs
and ensuring the quality use of medicines. By analysing
drug usage trends the DTC has become more involved in
cost containment and predicting budgetary needs.
The individual patient use (IPU) scheme was created
as a gatekeeping device for high-cost drugs. IPU drugs
are often requested for rare diseases where the drug has
limited evidence as standard treatment and for non-
approved indications. No funding from the States,
Territories or the Commonwealth Government is provided
for these drugs. They are generally high-cost drugs used
for a specific therapeutic indication. These drugs are not
available on the hospital fonnulary, nor have they been
approved by the hospital for the intended indication.
Therefore, the lPU scheme is used to allow prescribers to
access non-fonnulary drugs in exceptional cases.
The IPU scheme is managed through the DTC, which
faces certain difficulties. One of these difficulties is the
limited information available to conduct a complete
evaluation of safety and efficacy for these drugs.
These drugs can also represent a new therapeutic
modality such as biological therapy. Evidence supporting
applications through the IPU scheme may come from case
reports or case series of a small number of patients with
a single exposure. Estimates of cost effectiveness or any
other economic evaluation may be missing or poorly
documented due to the fact that, in the majority of cases,
the indication is not a Therapeutic Goods Administration
(TGA) approved indication (off-label).
All of these facts bring a range of economic, legal
and ethical issues to the IPU scheme. Even though
hospitals may have developed guidelines for use and
approval of high-cost drugs as a cost-containment
strategy, it is difficult to readily assess the outcomes of
the IPU scheme. Outcomes of interest include the clinical
consequences for the individual patient, as well as the
healthcare costs involved. Comprehensive data are
difficult to collect and interpret since there are limitations
in documentation, follow-up, and availability of
comparative and financial data. Consequently, the
purpose of this study was to document and describe the
IPU scheme at St Vincent's Hospital, Sydney and assess
the financial impact on the hospital drug expenditure.
Such review is a basis for evaluation of current processes
and consideration of alternative approaches.
METHOD
The study was conducted at St Vincent's Hospital,
Sydney, a 350-bcd university-affiliated, tertiary acute care
hospital. The IPU scheme was reviewed for consistency
of process and use of precedents. All submissions for IPU
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approval received between January 1997 and December
2001 were reviewed. Submissions were collected on a
calendar-year basis (January to December). Sources of
data included pharmacy department records, drug use
evaluation data records, DTC records, and dispensing
systems MED RECORD (version 5.36 DOS) for drugs
dispensed before November 1999 and STOCCA (version
3.7) for drugs dispensed after November 1999.
Acquisition prices of drugs were obtained from the
2001 inventory catalogue provided by STOCCA.
Information regarding the status of the indication being
approved was obtained from different sources including
the Schedule of Phamlaceutical Benefits, MIMS and the
TGA 1800 contact line:'" Data collection included
medication, approved indication, status of the indication
being approved, prescriber, ward, outcome of therapy,
person deciding the approval, approval date duration
and expiry, and the cost of therapy. The annual cost and
proportion of overall drug expenditure for each approval
was calculated. IPU approvals were excluded if data such
as course of therapy ~nd duration were not available
and if cost did not exceed $ 100 per year.
Statistical Analysis
A Microsoft Excel 2000 database was designed to store
and analyse data. Data were entered and validated by
perfonning manual checks against original sources. Data
for submissions and approvals were grouped per
calendar year. Each year was analysed separately to
account for alterations in the status of medications and
indications that occurred over time. Categories were used
to differentially describe available evidence rather than
funding source.
Special access scheme (SAS) unregistered drugs
made available under the provision of sections 19
and 18 of the Therapeutic Goods Act."
Non-TGA approved indication drugs marketed in
Australia but not for the intended indication (off-label).
TGA approved indication and not listed in PBS
subsidy criteria.
TGA approved indication and listed in PBS subsidy
criteria.
Data were summarised and the proportion of drug
expenditure and annual cost were compared using the
chi-square test for linear trend. Significance was set at
the 5% level.
RESULTS
The process of approval at St Vincent's Hospital is
outlined in Figure I. An [PU request fornl is filled out by
the prescriber and sent to the Director of Phannacy who,
according to the complexity and priority of the request,
either approved the request or asked for further evidence
to SUppOlt the indication. Following this, the Director of
Pharmacy approved the request or forwarded it to the
Chainnan of the DTC for a direct decision or referral to the
next DTC meeting. At this point, the request was either
approved or rejected. However, there were circumstances
where acute conditions needed immediate attention and
decisions could be made outside the DTe meeting
schedule. Once the drugs were approved an annotation·
was entered in the STOCCA dispensing system, with the
date of approval, indication and duration of the therapy.
There were no explicit criteria for IPU approvals.
Dose, duration of therapy, indication, failure to previous
treatment, rationale for use, evidence for use in the
specific indication, available level of evidence, safety,
clinical need and cost of course were the minimum
requirements for IPU submissions.
A total of 340 new submissions and 323 approvals
for IPU between 1997 and 2001 were reviewed. The
process was consistent for the drugs reviewed. Once a
drug was approved for a certain indication, submissions
for other patients with the same indication were
approved. A total of 33 literature reviews were supplied
(8.8% of the total submissions).
There was a trend that IPU submissions and
approvals had increased through the years (Figure 2).
There were a number of medications that despite being
approved were never dispensed to the patient (13). Two
submissions were withdrawn after being submitted.
IPU approvals for 1997 and 1998 were excluded from
further analysis since data such as course of therapy
























Figure I. Process of submission and approval of the individual patient use scheme at St Vincent's Hospital
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Table 2. Status of indicalions of drugs approved expressed
as percentages of the lotal number of individual patient
use approvals
1999 2000 2001 Total
Status (n = 61) (n = 77) (u =87) (n = 225)
SAS 6.6 3.9 9.2 6.7
Non TGA 60.7 77.9 62.1 67.1
Non HSD/PBS 16.4 5.2 14.9 12.0
PBS 16.4 10.4 11.5 12.4
















Figure 2. Submissions and approvals for new individual
patient use drugs
SAS =special access scheme; TGA =therapeutic goods
administration; HSD = highly specialised drugs; PBS =
phannaceutical benefits scheme
From 63 submissions in 1999, 61 new IPU
applications were approved for 31 different medications
and 51 patients. Mycophenolate (11 approvals)
accounted for 18% of the approvals, followed by
octreotide, erythropoietin and cyclosporin (8.2% each).
In 2000, the number of new IPU approvals increased to
77, for 37 medications and 75 patients. Mycophenolate
was still the most widely approved (22.9%) of the
approvals followed by pamidronate (12%), cyclosporin
and tacrolimus (4.8% each). By 2001, the number of
approvals increased to 87 for 20 medications in 79
patients. The medication most frequently approved was
pamidronate (18.4%) followed by mycophenolate
(17.2%) and gabapentin (10.3%). The approved
medications in order of frequency between 1999 and
200 I is listed in Table I.
Table 1. Most frequently approved individual patient use
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More than half of the medications (67.1%) were
approved for otT-label indications (Table 2). This group
was followed by medications with indications listed on
the PBS but not on the hospital fonnulary (12.4%). Third
group was those with TGA approval but not funded
through the HSD program or PBS (12%). The last group
was the special access scheme (SAS) medications with
6.7%. The 'other' classification in 2000 represents a single
approval of a tensoactive agent.
A report of clinical outcomes was requested for 71
out of the 225 approvals (31.5%). Of these 13 out of 71
(18%) were reported. The percentage of outcomes
requested was exactly the same in 1999 and 200 I. During
2000 the percentage requested was 48%, however, the
response rates were similar to both 1999 and 2000.
Applications for IPU were approved by the DTC or
delegated to the Chairman of the DTC or the Director of
Pharmacy. The Director of Phannacy was the person who
most frequently approved IPU applications (70.6%). The
proportion of approvals by the Director of Pharmacy
increased over the years. For a proportion of approvals
(11%), there was no available documentation of who
approved the IPU.
In 1999, the speciality with the greatest proportion of
approvals was immunology (23% of the 61 approvals),
followed by haematology (10%) and nephrology (8%). In
2000, the trend was similar with 29% of77 approvals being
for immunology, followed by haematology (12%) and lung
transplant (9%). As in previous years, immunology had
the highest proportion in 2001 (23%) followed by lung
transplant (13%) and haematology (10%).
As the number of approvals increased, so has the
cost of the IPU scheme. Between 1999 and 200 I the costs
have doubled (Figure 3). As the cost has increased each
year, so has the proportion of the drug expenditure being
consumed by the IPU scheme. The proportion of drug
expenditure on IPU increased significantly (p < 0.001) from
1.6% in 1999 to 3.6% in 200 I.
DISCUSSION
There was an apparent trend for the number of approvals
to increase over the years reviewed. The majority of these
approvals (67.1 %) were for off-label indications. Similar
percentages have been found in other hospitals in New
South Wales.'
Only )8% of the requests regarding clinical outcome
of the patient were reported by clinicians. In this study
there was no attempt by the investigator to separately
review outcomes through medical records. This would
not be feasible in routine practice, and would not reflect
the purpose of the scheme.
It was noted that the pattern of drugs submitted for
IPU approval have changed through the years (Table I).
Not only newly available agents were requested but also
older drugs such as cyclosporin, mycophenolate and
tacrolimus for varying off-label indications. As such the
process oflPU review was still required to ensure optimal
drug use and this may have influenced the request
patterns of drugs involved.
The documentation process allowed for the cost
issue of the IPU scheme to be analysed. The financial




















impact of the IPU scheme was substantial and increased
significantly (p < 0.001) from 1.6% of the drug
expenditure in 1999 to 3.6% in 2001. As an incidental
finding, the Director of Phannacy made the majority of
the approvals and there was a trend that the workload
associated with this increased over the years. It must
be borne in mind that the cost of the scheme not only
involves the cost of the drugs but also the cost of the
personnel administering this program. As a result of
this review the definition of high-cost drug for the
purpose of the IPU scheme was adopted as above $5000
per patient in any given year.
h might be suggested that the overall impact of the
IPU scheme, when compared with the entire drug
expenditure. is minimal. However, when dealing with a
capped budget and scarce resources, the question has
to be asked, 'Is it a fair distribution of resources to spend
3.6% of drug expenditure on only 79 patients?' The
decisions are not simply based on financial cost alone,
as ethical aspects play a significant role. The literature
to date has focused on different mechanisms of rationing
and principles such as distributive justice and human
resource allocation decisions. ll ,12 Still, it is difficult to
place value on a patient's wellbeing, and to measure the
impact it has for society, It seems that in some
circumstances the 'rule of rescue' is applied to high-cost
drugs. This means accepting some cost-ineffective
interventions for patients with rare catastrophic illness
who have no other treatment options. 13 Ongoing research
is required to explore the decision-making process with
regards to high-cost drugs.
Analysis of the current IPU scheme showed the need
for recording, monitoring, and evaluating the system and
other programs that influence drug costs. The resuits of
the project indicated that the number of approvals and
submissions for IPU had a tendency to increase over
time. The financial impact of the scheme was significant
and increased over the years studied. Revision and
ongoing improvement of the current system should be
considered in order to ensure efficient management of
this scheme.
Guidelines could be developed, implemented and
evaluated for this IPU scheme, which may then have
application in other Australian hospitals.
At St Vincent's Hospital, subsequent to this review,
a new policy and procedure for managing requests for
high-cost drugs for IPU was established. A high-cost
drugs subcommittee (operating under the auspices of
the DTC) was created to act as a forum for priority setting
and a way of improving the decision-making process.
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